A Phase 2 interventional study of cetuximab and lenalidomide in Colorectal Cancer, sponsored by Celgene Corporation. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-21.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 2, and was the 7th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, Spain
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 17 · Phase 3 5
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 171 across the 27 interventional studies, 124 across the 1 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
2 of the studies in Colorectal Neoplasms by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06544655Bristol-Myers SquibbA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | 2027-10-14 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination therapy of lenalidomide plus cetuximab
Drug: cetuximab · Drug: lenalidomide
Single agent therapy of lenalidomide
Drug: lenalidomide
Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
Also known as: Erbitux
Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
Also known as: Revlimid
Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period
The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period: If \<2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg. If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg. If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg. If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators.
Time frame: Up to Day 28 (Cycle 1)
Percentage of Participants With a Response to Treatment During the Proof of Concept Period
Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). Treatment response includes both complete response and partial response. * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline Analysis was not performed due to the early termination of the study.
Time frame: week 9 up to week 24
Kaplan-Meier Estimates for Progression Free Survival (PFS)
PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD), or death on study due to any cause. Analysis was not performed due to the early termination of the study.
Time frame: up to week 24
Kaplan-Meier Estimates for Duration of Response
Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR). Analysis was not performed due to the early termination of the study.
Time frame: up to week 24
Percentage of Participants With Disease Control
Known as the Disease Control Rate (DCR), participants with a complete response, partial response or stable disease contribute to the DCR. This analysis was not performed due to the early termination of the study.
Time frame: up to week 24
Kaplan-Meier Estimates for Overall Survival
Overall survival was defined as the time between randomization and death. It was intended that participants would be followed for up to 5 years following discontinuation from treatment. Analysis was not performed due to the early termination of the study.
Time frame: up to 5.5 years
Participants With Treatment-Emergent Adverse Events (TEAE)
TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE.
Time frame: up to week 28
| Milestone | Lenalidomide + Cetuximab (Safety Lead-in) | Lenalidomide (Proof of Concept) | Lenalidomide + Cetuximab (Proof of Concept) |
|---|---|---|---|
| Started | 8 | 0 | 0 |
| Completed | 6 | 0 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Milestone | Lenalidomide + Cetuximab (Safety Lead-in) | Lenalidomide (Proof of Concept) | Lenalidomide + Cetuximab (Proof of Concept) |
|---|---|---|---|
| Started | 0 | 22 | 21 |
| Intent to treat and safety populations | 0 | 21 | 21 |
| Completed | 0 | 14 | 18 |
| Not completed | 0 | 8 | 3 |
| Withdrew: Adverse event | 0 | 5 | 1 |
| Withdrew: Death | 0 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Never received study drug | 0 | 1 | 0 |
The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period: If \<2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg. If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg. If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg. If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators.
| participants | Lenalidomide Plus Cetuximab (Safety Lead-in) |
|---|---|
| Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period | 1 |
Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir. Participants with evidence of objective tumor response have the response confirmed with repeat assessments performed at the next scheduled scan.
| participants | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 0 | 0 |
| Stable Disease | 3 | 5 |
| Progressive Disease | 13 | 13 |
| Response Not Evaluable | 5 | 3 |
PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD), or death on study due to any cause. Analysis was not performed due to the early termination of the study.
No measurements were reported for this outcome.
Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR). Analysis was not performed due to the early termination of the study.
No measurements were reported for this outcome.
Known as the Disease Control Rate (DCR), participants with a complete response, partial response or stable disease contribute to the DCR. This analysis was not performed due to the early termination of the study.
No measurements were reported for this outcome.
Overall survival was defined as the time between randomization and death. It was intended that participants would be followed for up to 5 years following discontinuation from treatment. Analysis was not performed due to the early termination of the study.
No measurements were reported for this outcome.
TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE.
| participants | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) |
|---|---|---|---|
| >=1 TEAE | 8 | 20 | 21 |
| Serious TEAE | 5 | 9 | 9 |
| TEAE leading to discontinuing lenalidomide | 3 | 7 | 5 |
| TEAE leading to discontinuing cetuximab | 3 | NA | 6 |
| TEAE leading to reduction/interruption of lenalido | 2 | 6 | 9 |
| TEAE leading to reduction/interruption of cetuxima | 1 | NA | 7 |
| TEAE related to lenalidomide | 5 | 9 | 13 |
| TEAE related to cetuximab | 8 | NA | 19 |
| TEAE NCI CTC grade 3 or higher | 4 | 13 | 12 |
| TEAE NCI CTC grade 3+ related to lenalidomide | 3 | 4 | 4 |
| TEAE NCI CTC grade 3+ related to cetuximab | 2 | NA | 7 |
| Serious TEAE related to lenalidomide | 2 | 0 | 2 |
| Serious TEAE related to cetuximab | 2 | NA | 2 |
Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). Treatment response includes both complete response and partial response. * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline Analysis was not performed due to the early termination of the study.
No measurements were reported for this outcome.
Collected over up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide (Proof of Concept) | — | 9/21 (42.9%) | 16/21 (76.2%) |
| Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept) | — | 14/29 (48.3%) | 29/29 (100%) |
| Event | Lenalidomide (Proof of Concept) | Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept) |
|---|---|---|
| General Physical Health DeteriorationGeneral disorders | 2/21 | 3/29 |
| Abdominal painGastrointestinal disorders | 2/21 | 0/29 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/21 | 2/29 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/21 | 2/29 |
| DiarrhoeaGastrointestinal disorders | 0/21 | 2/29 |
| PyrexiaGeneral disorders | 1/21 | 1/29 |
| ConstipationGastrointestinal disorders | 1/21 | 0/29 |
| Large Intestine PerforationGastrointestinal disorders | 1/21 | 0/29 |
| Rectal ObstructionGastrointestinal disorders | 1/21 | 0/29 |
| AstheniaGeneral disorders | 1/21 | 1/29 |
| Event | Lenalidomide (Proof of Concept) | Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept) |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 6/21 | 20/29 |
| DiarrhoeaGastrointestinal disorders | 1/21 | 14/29 |
| FatigueGeneral disorders | 6/21 | 11/29 |
| NauseaGastrointestinal disorders | 4/21 | 10/29 |
| Abdominal painGastrointestinal disorders | 5/21 | 9/29 |
| AstheniaGeneral disorders | 6/21 | 9/29 |
| Dry skinSkin and subcutaneous tissue disorders | 0/21 | 8/29 |
| VomitingGastrointestinal disorders | 2/21 | 7/29 |
| AnorexiaMetabolism and nutrition disorders | 3/21 | 7/29 |
| ConstipationGastrointestinal disorders | 3/21 | 6/29 |
| Age, Customized(participants) | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) | Total |
|---|---|---|---|---|
| <= 65 years | 7 | 16 | 18 | 41 |
| >65 years | 1 | 5 | 3 | 9 |
| Sex: Female, Male(Participants) | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) | Total |
|---|---|---|---|---|
| Female | 4 | 9 | 9 | 22 |
| Male | 4 | 12 | 12 | 28 |
| Race/Ethnicity, Customized(participants) | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) | Total |
|---|---|---|---|---|
| Caucasian (White) | 8 | 21 | 20 | 49 |
| Other (Not Specified) | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Non-Hispanic or Latino | 8 | 21 | 21 | 50 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Lenalidomide Plus Cetuximab (Safety Lead-In) | Lenalidomide (Proof of Concept) | Lenalidomide Plus Cetuximab (Proof of Concept) | Total |
|---|---|---|---|---|
| 0 | 6 | 10 | 14 | 30 |
| 1 | 2 | 10 | 7 | 19 |
| 2 | 0 | 1 | 0 | 1 |
| 3-5 | 0 | 0 | 0 | 0 |
The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide